Now Playing
Opinion|Videos|June 14, 2023
MDS Diagnosis and Risk Stratification
James K McCloskey, MD, Jamie L Koprivnikar, MD, and Christina Cho, MD discuss the diagnosis of myelodysplastic syndrome (MDS) and the importance of risk stratification in guiding treatment decisions.
Advertisement
Episodes in this series
Advertisement
Related to this article
Poster sessions at WCLC 2026 detail how surgery, nursing, and pathology can contribute to the multidisciplinary care of patients with lung cancer.
A positive CHMP opinion supports the perioperative use of pembrolizumab plus enfortumab vedotin in resectable MIBC regardless of cisplatin eligibility.
Jasmine Zain, MD, described how pre-existing CHIP mutations should inform pre-infusion risk counseling and treatment selection.
T-DXd and Dato-DXd are now approved treatments in Japan for patients with breast cancer.
Data from the phase 3 EMBER-3 trial support the full approval of imlunestrant plus abemaciclib in this breast cancer population.
!["Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1cfb57db416943d8f8690afb0bc0d13aa3d90683-400x400.jpg?w=350&fit=crop&auto=format)
"Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
The European Medicines Agency’s CHMP recommended approval of relacorilant plus nab-paclitaxel for platinum-resistant ovarian cancer based on the ROSELLA trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
2
Screening for CHIP Mutations to Guide CAR T Cell Candidacy in Lymphoma
3
Daraxonrasib Receives FDA Breakthrough Therapy Status in 1L Metastatic PDAC
4
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
5